摘要
目的探究ArcCheck-3DVH在直肠癌与宫颈癌调强放疗计划上的三维剂量验证效果,并探讨该设备在2组计划剂量验证结果上的差异。方法选取基于Monaco 6.1计划系统的19例直肠癌与21例宫颈癌计划为研究对象。采用SNC Patient计算并比较diff/Dist=3 mm/3%、阈值TH=10条件下放疗计划系统(Treatment Planning System,TPS)与ArcCheck模体测得的γ通过率。再采用3DVH系统重建靶区与危及器官的三维剂量分布,比较其与TPS在D98%(98%的靶区体积接受的最小剂量)、D_(2%)(2%的靶区体积接受的最小剂量)和D_(mean)(平均剂量)等参数条件下的剂量差异。结果19例直肠癌计划在SNC Patient上计算得到的平均γ通过率为99.46%±0.70%,大于3DVH的98.88%±0.46%,且剂量差异具有统计学意义(P<0.05)。临床靶区的γ通过率均大于94%且在D_(2%)下剂量差异存在统计学意义(P<0.05)。危及器官的γ通过率均大于95%且除小肠V40(器官接受至少40 Gy剂量的体积百分比)、脊髓D_(mean)外,其余危及器官在各参数下差异均无统计学意义(P>0.05)。21例宫颈癌计划在SNC Patient上计算得到的γ通过率为99.67%[99.35%,99.95%],大于3DVH的98.49%[98.05%,98.95%],且两者之间的差异具有统计学意义(P<0.05)。临床靶区的γ通过率均大于93.70%并在D_(mean)和D_(2%)下的剂量差异具有统计学意义(P<0.05)。危及器官的γ通过率均大于91%,且除直肠V30(器官接受至少30 Gy剂量的体积百分比)、脊髓D_(mean)外,其余器官在各参数下的剂量差异均具有统计学意义(P<0.05)。结论ArcCheck-3DVH系统不仅能整体评估直肠癌和宫颈癌容积旋转调强放疗计划的剂量验证结果,还能进一步提供靶区与危及器官的测量重建剂量和与TPS计算剂量之间的差异。
Objective To explore the 3D dose validation effect of ArcCheck-3DVH on intensity modulated radiotherapy for rectal cancer and cervical cancer,and to explore the difference of the results for ArcCheck-3DVH on planned dose validation for two groups.Methods A total of 19 cases of rectal cancer and 21 cases of cervical cancer were retrospectively collected based on the Monaco 6.1 planning system.SNC Patient was used to calculate and compare theγpassing rates measured by treatment planning system(TPS)and ArcCheck model under the conditions of diff/Dist=3 mm/3%,Threshold=10.Then 3DVH system was used to reconstruct the three-dimensional dose distribution of target and organs at risk,and the difference between it and TPS was compared under D98%(the minimum dose received at 98%target area volume),D_(2%)(the minimum dose received at 2%target area volume)and D_(mean)(the average dose)parameters.Results The averageγpassing rate of 19 rectal cancer plans calculated on SNC Patient was 99.46%±0.7%,which was higher than 98.88%±0.46%in 3DVH,and the dose difference was statistically significant(P<0.05).Theγpassage rates in clinical target were all greater than 94%,and there were significant differences in D_(2%)(P<0.05).Theγpassing rates of the organs at risk were all greater than 95%and there was no significant difference in the parameters of other organs at risk except small intestine V40(the volume percentage of organs receiving 40 Gy dose)and spinal cord D_(mean)(P>0.05).Theγpassing rate of 21 cervical cancer plans calculated on SNC Patient was 99.67%[99.35%,99.95%],which was higher than 98.49%[98.05%,98.95]%of 3DVH,and the difference between the two was statistically significant(P<0.05).Theγpassage rates in clinical target areas were all greater than 93.70%,and there were significant differences in D_(mean) and D_(2%)(P<0.05).Theγpassing rates of the organs at risk were all greater than 91%,and the dose differences in the parameters of other organs except the V30(the volume percentage of organs receiving 30 Gy dose)and the D_(mean) of the spinal cord were statistically significant(P<0.05).Conclusion The ArcCheck-3DVH system can not only evaluate the dose validation results of the VMAT program for rectal and cervical cancer as a whole,but also further provide the difference between the measured reconstruction dose and the calculated dose of TPS for the target area and the organ at risk.
作者
郑超
钟青松
ZHENG Chao;ZHONG Qingsong(Radiotherapy Center,Zhujiang Hospital of Southern Medical University,Guangzhou Guangdong 510280,China.)
出处
《中国医疗设备》
2024年第11期51-55,68,共6页
China Medical Devices
